Advertisement

Meeting Coverage

Novel drug combination for recurrent ovarian cancer

Mirvetuximab soravtansine, a folate receptor-targeting antibody-drug conjugate, in combination with bevacizumab, demonstrated impressive anti-cancer activity in the phase 1b FORWARD II trial.  Mirvetuximab soravtansine (MIRV) is...

Read More
Advertisement